Allopurinol, a traditionally specific inhibitor of xanthine oxidase (XO), failed to improve kidney outcomes among patients with Type 1 diabetes accompanied by early-to-moderate DKD in the PERL study [10]. Here, XDH is linked to diabetic kidney disease.